Quick Answer
Hepion Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $0.88 (loss) per share for the year ending 2025.
- Hepion Pharmaceuticals, Inc. showed an increase of +99.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Hepion Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $0.27 (loss) per share | Q1 2019: $0.11 (loss) per share | Q1 2020: $0.97 (loss) per share | Q2 2020: $0.58 (loss) per share | Q3 2020: $0.69 (loss) per share | Q1 2021: $0.12 (loss) per share | Q2 2021: $0.10 (loss) per share | Q3 2021: $0.12 (loss) per share | Q1 2022: $1.82 (loss) per share | Q2 2022: $5.22 (loss) per share | Q3 2022: $2.24 (loss) per share | Q1 2023: $3.48 (loss) per share | Q2 2023: $3.68 (loss) per share | Q3 2023: $2.74 (loss) per share | Q1 2024: $28.13 (loss) per share | Q2 2024: $34.00 (loss) per share | Q3 2024: $36.21 (loss) per share | Q1 2025: $2.15 (loss) per share | Q2 2025: $0.09 (loss) per share | Q3 2025: $0.04 (loss) per share.
- Over the full 9 years of available data (2016 to 2025), Hepion Pharmaceuticals, Inc.'s Earnings Per Share Diluted has declined by 39.7%.
- Historical annual values: Fiscal year 2025: $0.88 (loss) per share | Fiscal year 2024: $107.35 (loss) per share | Fiscal year 2023: $616.07 (loss) per share | Fiscal year 2022: $11.90 (loss) per share | Fiscal year 2021: $0.47 (loss) per share | Fiscal year 2020: $2.10 (loss) per share | Fiscal year 2018: $1.39 (loss) per share | Fiscal year 2017: $2.41 (loss) per share | Fiscal year 2016: $0.63 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: